Default company panoramic image
718df395 2e68 4255 8aba ad3756524243

BioKier, Inc.

BioKier is a clinical-stage company developing an oral product for diabetes patients that mimics the anti-diabetes effects of gastric bypass surgery.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Chapel Hill, NC, USA
  • Currency USD
  • Founded October 2008
  • Employees 4
  • Incorporation Type C-corp
  • Website biokier.com

Company Summary

BioKier is developing a proprietary oral product for management of blood glucose, designed to mimic the beneficial effects on diabetes seen from bariatric surgery. Bariatric surgery is currently the most effective treatment for diabetes. Because BioKier’s product is a proprietarily formulated amino acid it can qualify under FDA law as a medical food, thus avoiding much of the cost and time required for FDA approval of a prescription drug.

Team

  • E16cf2e8 51f4 4765 95f9 c60ac4a8a3db
    CEO and CSO

    Jerzy "George" Szewczyk, PhD: Co-Founder, CEO & CSO was a founder of BioKier and devised the concept and IP. He has over 15 years industry R&D experience in diabetes, obesity, and metabolic syndrome at GSK where he led multidisciplinary teams in drug discovery and development, advancing drugs to clinical trials. Prior to GSK, he was a research scientist at Duke University.

  • Photo
    President and COO

    Roger Nolan, PhD is a cofounder of BioKier and has 25 years R&D experience in diabetes, oncology, cardiovascular diseases in small and large companies. He has managed discovery, preclinical, and clinical development of drugs; including an advanced diabetes drug licensed to Sanofi.

  • Dbc90141 e3b4 4166 8250 298a209eb58f
    Vice President, CFO

    W. Bennett Love: Vice President, CFO made an investment in BioKier and joined management in 2013. He has 20+ year development-stage biotech management background, with experience in capital markets, VC fundings, pharma collaborations, and exits (inc. 2 IPOs). Priors include Sphinx, Incara, Ercole, Synereca.

Advisors

  • Default avatar
    David D’Alessio, M.D., Duke University Dr. D’Alessio is Professor of Medicine, and Director of the Division of Endocrinology, Metabolism and Nutrition at Duke University Medical Center
    Unconfirmed
    Default avatar
    Fiona M Gribble DPhil BM BCh, Addenbrooke’s Hospital, Cambridge, UK, Professor of Endocrine Physiology and Honorary Consultant in Clinical Biochemistry at the University of Cambridge Institute for Medical Research and Institute of Metabolic Science
    Unconfirmed
    Default avatar
    L. Kristin Newby, MD, MHS, Professor of Medicine, Cardiology, Co-Director, Duke Cardiac Care Unit, Duke University Medical Center Dr. Newby is Professor of Medicine in the Division of Cardiology, Co-Director of the Cardiac Care Unit at Duke
    Unconfirmed
  • Default avatar
    Professor Abdul Basit, Professor of Pharmaceutics at the School of Pharmacy, University College London (UCL) Abdul’s is an international authority on oral drug delivery and absorption and gastroenterology.
    Unconfirmed
    Default avatar
    Fran Martin, RPh, VVI, LLC Fran Martin is an accomplished pharmaceutical executive with end-to-end commercialization expertise encompassing discovery, development, launch and lifecycle management, with many years' experience at GlaxoSmithKline
    Unconfirmed

Previous Investors

  • Default avatar
    Broadview Ventures Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early-stage ventures.
    Unconfirmed